9 Facts About Lichen Sclerosus and Menopause That Women Urgently Need to Know
The number of women who've spent years being told it's 'just dryness' or 'probably thrush' before someone finally looked properly and said lichen sclerosus — it's staggering and it's heartbreaking. This is one of those conditions where knowing the name, and knowing to push for a proper examination, can genuinely change the course of someone's life. If something down there has felt wrong for longer than it should, this page is worth reading carefully.
Learn more about Rose →Lichen Sclerosus Is Not the Same as GSM — and Treating It Like GSM Can Make Things Worse
Genitourinary Syndrome of Menopause (GSM) causes vaginal dryness and thinning due to estrogen loss, but lichen sclerosus (LS) is a distinct chronic inflammatory skin condition that causes the vulvar skin to become white, fragile, and structurally scarred. Both worsen during menopause, and both involve genital discomfort, which is precisely why LS is so frequently missed or mislabelled. Using only vaginal moisturisers or low-dose vaginal estrogen — the standard approach for GSM — will not treat LS and may allow progressive scarring to continue unchecked.
Estrogen Loss Directly Worsens Lichen Sclerosus — Menopause Is a High-Risk Window
LS has a bimodal peak: it appears in prepubertal girls and again in postmenopausal women, a pattern that strongly implicates low estrogen as a driving factor in its onset and progression. The thinning and atrophy of vulvar tissue caused by estrogen decline creates a more vulnerable environment where LS can flare, spread, and cause greater architectural damage. This doesn't mean estrogen causes LS — the relationship is more nuanced — but it does mean perimenopause is a critical window to catch it early.
The Classic Symptoms Are Specific — and Women Should Know Them by Name
LS typically presents as intense vulvar itching (often worse at night), white or ivory patches of skin on the vulva or around the anus, skin that tears or bruises easily, and progressive narrowing of the vaginal opening. Over time, the labia minora can fuse or shrink, and the clitoral hood may become adherent — changes that are visible on examination and, importantly, irreversible if left untreated. Any woman experiencing persistent vulvar itch, pale skin changes, or unexplained splitting of the skin after menopause should request a proper vulvoscopic examination, not just a swab.
Diagnosis Requires a Physical Examination — and Many GPs Are Not Performing One
A significant driver of diagnostic delay is that women describe their symptoms verbally — itching, discomfort, painful sex — and are prescribed antifungals or reassured without the vulva ever being properly examined. A confident clinical diagnosis of LS can usually be made visually by an experienced clinician; a biopsy is reserved for uncertain cases or where malignancy is suspected. Women should know they have every right to ask for a visual vulvar examination, and if a GP is uncomfortable performing one, a referral to dermatology or vulvar health specialist is entirely appropriate.
First-Line Treatment Is a Potent Topical Steroid — Not Hormones Alone
The gold-standard treatment for LS is a high-potency topical corticosteroid, typically clobetasol propionate 0.05%, applied to the affected area on a structured reducing regimen. This is not the same as the mild hydrocortisone found in over-the-counter creams, and using the wrong strength will not adequately suppress the inflammation driving the scarring process. Topical estrogen or systemic HRT may be used alongside steroids to address concurrent GSM and support skin integrity, but they do not treat LS as a standalone therapy.
Lichen Sclerosus Carries a Small but Real Risk of Vulvar Cancer
Untreated or poorly controlled LS is associated with an approximately 3–5% lifetime risk of developing vulvar squamous cell carcinoma — a risk that is substantially reduced, though not eliminated, with consistent treatment and monitoring. The cancer risk is one of the most important reasons why LS should never be treated as a minor nuisance or left to manage itself. Women with a confirmed diagnosis should be on a regular review schedule — typically annual — so that any suspicious changes, such as new lumps, ulcers, or areas of thickening, are caught early.
Architectural Scarring Is Permanent — But It Can Be Stopped
One of the most distressing aspects of LS is that the structural changes it causes — fusion of the labia, narrowing of the vaginal introitus, burying of the clitoris — cannot be reversed once they have occurred. This is not a reason for despair; it is a reason for urgency. Consistent use of the correct treatment has been shown to halt progression and, in some women, allow modest softening of existing changes, but the window to preserve anatomy is real and time-limited.
LS Can Severely Impact Sexual Function and Mental Health — and This Deserves Acknowledgement
Dyspareunia (painful sex), loss of sexual sensation due to clitoral involvement, and the psychological weight of a chronic vulvar condition are well-documented consequences of untreated LS. Studies consistently show significantly elevated rates of anxiety, depression, and sexual dysfunction in women with LS compared to matched controls. Acknowledging this impact is part of good care — women should not be expected to simply tolerate these effects, and pelvic floor physiotherapy, psychosexual counselling, and appropriate pain management all have a legitimate role alongside medical treatment.
LS Is a Lifelong Condition — But It Is Manageable With the Right Support
There is currently no cure for LS, and women should be clear-eyed about the fact that it requires long-term management rather than a short course of treatment followed by discharge. However, the majority of women who receive an accurate diagnosis and adhere to a maintenance steroid regimen report good symptom control and protection from further progression. The goal of care is a normal, comfortable, functional life — and for most women with access to informed medical support, that goal is genuinely achievable.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.